Date | Price Target | Rating | Analyst |
---|---|---|---|
9/10/2024 | Buy → Neutral | BTIG Research | |
1/5/2023 | $4.00 | Sector Outperform | Scotiabank |
12/12/2022 | $3.50 | Buy | BTIG Research |
7/18/2022 | $12.00 | Outperform | Oppenheimer |
DEFA14A - Bionano Genomics, Inc. (0001411690) (Filer)
8-K - Bionano Genomics, Inc. (0001411690) (Filer)
DEFA14A - Bionano Genomics, Inc. (0001411690) (Filer)
SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) announced today that it has adjourned its Special Meeting of Stockholders held on October 2, 2024 (the "Special Meeting") because a quorum was not present at the time of meeting. Based on preliminary reports as of October 2, 2024, only 22.5% of total shares outstanding as of the record date have submitted their votes, whereas 33.3% of total shares outstanding as of the record date are necessary to satisfy the quorum requirements for a meeting. Based on the preliminary reports from the votes submitted as of October 2, 2024, approximately 74.5% of votes represented in person or by proxy at the Special Meeting w
SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9th, 2024. Conference & Webcast Details Date:September 9, 2024Time:11:00 a.m. to 11:30 a.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:Link to Register A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 30 days. About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to revea
Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023Sold 6,165 nanochannel array flowcells in Q2 2024, which represents a 13% decrease from the number of flowcells sold in Q2 2023The editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignanciesConference call today, August 7th, 2024 at 4:30 PM ET SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE
QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l
BTIG Research downgraded Bionano Genomics from Buy to Neutral
Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00
BTIG Research resumed coverage of Bionano Genomics with a rating of Buy and set a new price target of $3.50
SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, August 7th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/jojadok2/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 8th, 2024Time:4:30 p.m. ETParticipant Dial-In:Toll Free: 1-833-630-1956International: 1-412-317-1837Webcast Link:https://edge.media-server.com/mmc/p/5z343pph/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor re
Q4 2023 revenue was $10.7 million, which represents a 30% increase over Q4 2022FY 2023 revenue was $36.1 million, which represents a 30% increase over FY 2022Reached installed base of 326 optical genome mapping (OGM) systems as of YE 2023; increase of 36% over the 240 installed systems as of YE 2022Sold 26,444 nanochannel array flowcells in FY 2023, which represents a 72% increase over the flowcells sold in FY 2022Conference call today, March 5, 2024 at 4:30 PM ET SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2023 and revenue outlook for 2024. "2023 was a year in
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
3 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) comparing optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs).Multiple myeloma is a type of blood cancer originating in the plasma cell, known as a plasma cell neoplasm (PCN), and though sensitive and accurate identification of genetic abnormalities in MM samples is critical for patient risk stratification, predication of response to therapy options, and understanding of pathogenesis, many genome analysis methodologies, including fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA), are li
A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applicationsTwo scientific posters featuring results from OGM applications in cell manufacturing and bioprocessing applications will be presented at the conferenceSAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced its participation in the International Society for Stem Cell Research (ISSCR) Annual Meeting 2024 with a broad range of content cove
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)